-
Mashup Score: 5Dietary interventions a promising first line treatment for IBS - 10 day(s) ago
Dietary interventions such as low FODMAP should be considered a potential first-line treatment for patients with IBS, outperforming symptom-targeted medication in reducing symptom severity, a study suggests. However, all interventions in the single centre study resulted in significant and clinically meaningful efficacy at improving gastrointestinal, psychological and non-gastrointestinal somatic symptoms, and quality of life, the […]
Source: thelimbic.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 12
A top-down approach to treating patients newly diagnosed with Crohn’s disease is superior to an accelerated step-up approach, according to results presented at ECCO 24 Congress. Dr Nurulamin Noor, from the Department of Gastroenterology at Cambridge University Hospitals NHS Foundation Trust in the UK, presented results from the PROFILE study, the first biomarker-stratified comparison of […]
Source: thelimbic.comCategories: General Medicine News, GastroenterologyTweet-
Top-down better than step-up approach to Crohn’s disease: PROFILE studym, via @thelimbicgastro https://t.co/kxbcAUQvjK
-
-
Mashup Score: 2Key Advances in CUP - 3 month(s) ago
Join online as an expert panel provides important updates in Cancer of Unknown Primary, with a focus on practice-shaping data presented at ESMO 2023 and new recommendations on the role of genomic profiling in the diagnosis and treatment of CUP. Hosted by Professor Linda Mileshkin Director of Medical Oncology, Peter MacCallum Cancer Centre PANEL Dr […]
Source: thelimbic.comCategories: General Medicine News, Oncologists2Tweet-
RT @thelimbiconc: REGISTER: https://t.co/eCL1zZzY1i An expert panel provides important updates in Cancer of Unknown Primary, focusing on pr…
-
-
Mashup Score: 14Botox a new therapy for faecal incontinence: Lancet - 3 month(s) ago
Intrarectal botox injections can halve faecal incontinence and urgency episodes in treatment-resistant patients, according to the first randomised-controlled trial to investigate the short-term efficacy of the potential new therapy. French gastroenterologists recruited 200 adults with faecal incontinence who were considered refractory to first-line treatments and who had at least one urgency or faecal incontinence episode […]
Source: thelimbic.comCategories: General Medicine News, GastroenterologyTweet-
Botox a new therapy for faecal incontinence https://t.co/XtjYm8PbtR via @thelimbicgastro
-
-
Mashup Score: 9Non-coeliac gluten sensitivity a nocebo effect: study - 5 month(s) ago
Gastrointestinal symptoms of gluten sensitivity in people without coeliac disease are a nocebo effect driven by negative expectations, study findings suggest. A prospective blinded trial of gluten and placebo ingestion in participants with non-coeliac gluten sensitivity found that gastrointestinal symptoms were experienced more frequently by those who had high expectations of symptoms. Conducted by research […]
Source: thelimbic.comCategories: General Medicine News, GastroenterologyTweet-
Non-coeliac gluten sensitivity a nocebo effect: study https://t.co/Wco9Kd8hOu via @the_limbic
-
-
Mashup Score: 1[VIDEO] Updates in CLL: Managing BTK inhibitor off-target effects - 6 month(s) ago
Dr Renata Walewska moderates a case-based panel discussion on the management of adverse events with BTK inhibitors, including off-target effects of clinical concern. Independently created content, funded by BeiGene UK Ltd. Thank you to Beigene for providing sponsorship that made this project possible.
Source: thelimbic.comCategories: General Medicine News, Hem/OncsTweet-
RT @thelimbichaemUK: WATCH: https://t.co/Hb2v7pFive The recent MHRA approval of the second-generation BTK inhibitor zanubrutinib for patien…
-
-
Mashup Score: 2ESMO 2023 – Skin cancer highlights through an Australian lens - 6 month(s) ago
Join online as a panel of experts presents their selection of skin cancer highlights from the ESMO 2023 Annual Meeting and discusses the impacts for patient care in Australia. Hosted by Professor Georgina Long AO Co-Medical Director of Melanoma Institute Australia (MIA), The University of Sydney. PRESENTING PANEL Associate Professor Sydney Ch’ng. Associate Professor of […]
Source: thelimbic.comCategories: General Medicine News, Oncologists2Tweet-
RT @thelimbiconc: REGISTER: https://t.co/u7pJKTv0o3 Our expert panel hosted by @ProfGLongMIA will deep dive into key Skin cancer updates fr…
-
-
Mashup Score: 1WEBINAR: Update and Debate in Myeloma - 6 month(s) ago
Join the limbic for an update on the key developments in clinical practice for myeloma in the UK over the last 12 months, along with a debate on whether CAR T-cell therapy will be usurped by bispecific therapy in the treatment of myeloma. Hosted by Prof. Graham Jackson. Consultant Haematologist at Newcastle Hospitals Trust, Newcastle upon Tyne […]
Source: thelimbic.comCategories: General Medicine News, Hem/OncsTweet-
RT @thelimbichaemUK: REGISTER: https://t.co/9DiIy5t4cL Join us for a discussion on the key developments in myeloma in the UK & whether CAR…
-
-
Mashup Score: 3PODCAST: Supportive care in haemato-oncology: Treatment toxicities - 7 month(s) ago
Supportive care in haemato-oncology In this four-part educational series on supportive care in haemato-oncology, our team of expert clinicians will guide you through what supportive care means in blood cancers, managing infection, dealing with treatment toxicities, and psychosocial support and palliative care. We will discuss whether clinicians and patients are always on the same page […]
Source: thelimbic.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @thelimbichaemUK: LISTEN: https://t.co/o46bNX0maY In this episode, @profBigG and @profghjackson discuss managing toxicities associated w…
-
-
Mashup Score: 1VIDEO: Professor Srihari Naidu insights from the VALOR-HCM study - 7 month(s) ago
In the VALOR-HCM trial, mavacamten reduced the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy. Speaking at the recent CSANZ 2023 meeting in Adelaide, Professor Srihari Naidu of Westchester Medical Centre, New York, explained the real world impact of the benefits of the selective allosteric and reversible cardiac myosin inhibitor for patients […]
Source: thelimbic.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @thelimbiccardio: WATCH: https://t.co/zviHwLoOLW Prof @SrihariNaiduMD explains insights from the VALOR-HCM study - discussing the benefi…
-
Dietary interventions a promising first line treatment for IBS: https://t.co/SYhJNc46Tx via @thelimbicgastro #GITwitter